scholarly journals Evaluation of proper prescribing of cardiac medications at hospital discharge for patients with acute coronary syndromes (ACS) in two Lebanese hospitals

SpringerPlus ◽  
2014 ◽  
Vol 3 (1) ◽  
Author(s):  
Marwan Sheikh-Taha ◽  
Zeinab Hijazi
BMJ ◽  
2004 ◽  
Vol 328 (7453) ◽  
pp. 1413-1414 ◽  
Author(s):  
N F Murphy ◽  
K MacIntyre ◽  
S Capewell ◽  
S Stewart ◽  
J Pell ◽  
...  

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Yong Huo ◽  
Stephen W Lee ◽  
Jitendra P Sawhney ◽  
Hyo-Soo Kim ◽  
Rungroj Krittayaphong ◽  
...  

Introduction: Guidelines recommend dual-antiplatelet therapy (DAPT) for 12 months in patients with acute coronary syndromes (ACS). Information on patterns and duration of DAPT use after hospital discharge in ACS patients in Asia is sparse. Objective: We describe changes in real-life antithrombotic management patterns (AMPs) up to 2-y post discharge based on data from the EPICOR Asia study (NCT01361386). Methods: This observational study enrolled 12 922 hospital survivors post ACS from 218 hospitals in 8 countries/regions in Asia. Data were collected from symptom onset for the index event (ST-segment elevation myocardial infarction [STEMI] 51.2%, non-STEMI (NSTEMI) 19.9%, or unstable angina [UA] 28.9%), during hospitalization, at discharge and over 2 y follow-up. Results: Overall, 90.6% of patients were on DAPT at hospital discharge which declined to 79.6%, 71.8%, 53.7%, and 45.6% at 6, 12, 18, and 23 months post discharge (Fig). At discharge, most patients (87.6%) received aspirin + clopidogrel, with 79.5%, 71.8%, 53.6%, and 45.4% on this combination at 6, 12, 18, and 23 months. At discharge only 3.0% of patients received aspirin + prasugrel and 1.7% of patients received aspirin + cilostazol. Only 8.3% of patients were on single antiplatelet therapy (SAPT) at discharge with 12.2%, 15.6%, 28.1%, and 30.3% on SAPT at 6, 12, 18, and 23 months post discharge; aspirin being the most commonly used single agent. No notable differences were seen among index event groups. Of the patients on DAPT at discharge, STEMI 93.4%; NSTEMI 90.2%; UA 85.9%, comparable proportions across groups remained on DAPT at 23 months follow up; STEMI 51.0%; NSTEMI 51.9%; UA 47.6%. Conclusions: Most ACS patients remain on DAPT at 12 months and around half remain at 23 months post-discharge. Further study should assess between-country differences, the benefit/risk balance from prolonged DAPT, why DAPT is discontinued before 12 months, and impact on clinical outcomes.


2006 ◽  
Vol 166 (7) ◽  
pp. 806 ◽  
Author(s):  
Pierluigi Tricoci ◽  
Matthew T. Roe ◽  
Jyotsna Mulgund ◽  
L. Kristin Newby ◽  
Sidney C. Smith ◽  
...  

2018 ◽  
Vol 72 (16) ◽  
pp. C114
Author(s):  
Xin Du ◽  
Yingxue Li ◽  
Tiange Chen ◽  
Xiang Li ◽  
Xuedan You ◽  
...  

2012 ◽  
Vol 34 (1) ◽  
pp. 26-34 ◽  
Author(s):  
Gregory M. Peterson ◽  
Angus Thompson ◽  
Lisa K. Pulver ◽  
Marion B. Robertson ◽  
David Brieger ◽  
...  

Author(s):  
Tatsuhiko Otsuka ◽  
Sarah Bär ◽  
Sylvain Losdat ◽  
Raminta Kavaliauskaite ◽  
Yasushi Ueki ◽  
...  

Background Complete revascularization reduces cardiovascular events in patients with acute coronary syndromes (ACSs) and multivessel disease. The optimal time point of non–target‐vessel percutaneous coronary intervention (PCI) remains a matter of debate. The aim of this study was to investigate the impact of early (<4 weeks) versus late (≥4 weeks) staged PCI of non–target‐vessels in patients with ACS scheduled for staged PCI after hospital discharge. Methods and Results All patients with ACS undergoing planned staged PCI from 2009 to 2017 at Bern University Hospital, Switzerland, were analyzed. Patients with cardiogenic shock, in‐hospital staged PCI, staged cardiac surgery, and multiple staged PCIs were excluded. The primary end point was all‐cause death, recurrent myocardial infarction and urgent premature non–target‐vessel PCI. Of 8657 patients with ACS, staged revascularization was planned in 1764 patients, of whom 1432 patients fulfilled the eligibility criteria. At 1 year, there were no significant differences in the crude or adjusted rates of the primary end point (7.8% early versus 10.8% late, hazard ratio [HR], 0.72 [95% CI, 0.47–1.10], P =0.129; adjusted HR, 0.80 [95% CI, 0.50–1.28], P =0.346) and its individual components (all‐cause death: 1.5% versus 2.9%, HR, 0.52 [95% CI, 0.20–1.33], P =0.170; adjusted HR, 0.62 [95% CI, 0.23–1.67], P =0.343; recurrent myocardial infarction: 4.2% versus 4.4%, HR, 0.97 [95% CI, 0.475–1.10], P =0.924; adjusted HR, 1.03 [95% CI, 0.53–2.01], P =0.935; non–target‐vessel PCI, 3.9% versus 5.7%, HR, 0.97 [95% CI, 0.53–1.80], P =0.928; adjusted HR, 1.19 [95% CI, 0.61–2.34], P =0.609). Conclusions In this single‐center cohort study of patients with ACS scheduled to undergo staged PCI after hospital discharge, early (<4 weeks) versus late (≥4 weeks) staged PCI was associated with a similar rate of major adverse cardiac events at 1 year follow‐up. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02241291.


2020 ◽  
Vol 75 (11) ◽  
pp. 13
Author(s):  
Pedro Gabriel Melo De Barros E Silva ◽  
Otavio Berwanger ◽  
Renato Nakagawa ◽  
Thiago Macedo ◽  
Oscar Dutra ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document